## Martijn F Hoes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2506850/publications.pdf

Version: 2024-02-01

		623734	839539
19	727	14	18
papers	citations	h-index	g-index
			1006
20	20	20	1206
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. European Journal of Heart Failure, 2018, 20, 910-919.	7.1	225
2	Selenium and outcome in heart failure. European Journal of Heart Failure, 2020, 22, 1415-1423.	7.1	84
3	Red-light-sensitive BODIPY photoprotecting groups for amines and their biological application in controlling heart rhythm. Chemical Communications, 2020, 56, 5480-5483.	4.1	53
4	Modeling Human Cardiac Hypertrophy in Stem Cell-Derived Cardiomyocytes. Stem Cell Reports, 2018, 10, 794-807.	4.8	49
5	Dynamic loading of human engineered heart tissue enhances contractile function and drives a desmosome-linked disease phenotype. Science Translational Medicine, 2021, 13, .	12.4	48
6	Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology. Journal of Clinical Medicine, 2022, 11, 125.	2.4	45
7	Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH. Science Translational Medicine, 2017, 9, .	12.4	36
8	Concise Review: The Current State of Human In Vitro Cardiac Disease Modeling: A Focus on Gene Editing and Tissue Engineering. Stem Cells Translational Medicine, 2019, 8, 66-74.	<b>3.</b> 3	27
9	The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. European Journal of Heart Failure, 2020, 22, 2102-2111.	7.1	24
10	Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy. Nature Communications, 2021, 12, 5180.	12.8	24
11	Pathophysiology and risk factors of peripartum cardiomyopathy. Nature Reviews Cardiology, 2022, 19, 555-565.	13.7	21
12	In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles. Cardiovascular Research, 2020, 116, 1875-1886.	3.8	20
13	Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart. Journal of Internal Medicine, 2020, 288, 491-506.	6.0	20
14	Additional burden of iron deficiency in heart failure patients beyond the cardioâ€renal anaemia syndrome: findings from the <scp>BIOSTATâ€CHF</scp> study. European Journal of Heart Failure, 2022, 24, 192-204.	7.1	20
15	Selenoprotein DIO2 Is a Regulator of Mitochondrial Function, Morphology and UPRmt in Human Cardiomyocytes. International Journal of Molecular Sciences, 2021, 22, 11906.	4.1	13
16	Human iPSC-Derived Cardiomyocytes of Peripartum Patients With Cardiomyopathy Reveal Aberrant Regulation of Lipid Metabolism. Circulation, 2020, 142, 2288-2291.	1.6	8
17	Peripartum cardiomyopathy: Euro Observational Research Program. Netherlands Heart Journal, 2014, 22, 396-400.	0.8	6
18	Young@Heart: empowering the next generation of cardiovascular researchers. Netherlands Heart Journal, 2020, 28, 25-30.	0.8	1

#	Article	IF	CITATIONS
19	Abstract 19908: 5-oxoprolinase: a Novel Cardiac Mediator of the Oxidative Stress Response in the Failing Heart. Circulation, 2014, 130, .	1.6	0